This expression of MHC II by tumour cells might be of particular importance with regard to the observation that the occurrence of CD4+ lymphocytes before initiation of IFN-α treatment or biochemotherapy was significantly correlated to therapeutic response (Håkansson et al, 1996,2001). The gene discussed is CD4; the disease is neoplasm.